Page last updated: 2024-10-24

calmidazolium and B16 Melanoma

calmidazolium has been researched along with B16 Melanoma in 1 studies

calmidazolium: powerful inhibitor of or red blood cell Ca++-ATPase & Ca++ transport into inside-out red blood cell vesicles; RN refers to chloride; structure in first source; an antagonist of calmodulin
calmidazolium : An imidazolium ion that is imidazolium cation substituted by a bis(4-chlorophenyl)methyl group at position 1 and a 2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl group at position 3. It acts as an antagonist of calmodulin, a calcium binding messenger protein.

Research Excerpts

ExcerptRelevanceReference
"Nifedipine was included as the standard or reference compound."1.28In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II). ( Honn, KV; Nelson, KK; Onoda, JM; Taylor, JD, 1989)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Onoda, JM1
Nelson, KK1
Taylor, JD1
Honn, KV1

Other Studies

1 other study available for calmidazolium and B16 Melanoma

ArticleYear
In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
    Cancer research, 1989, Jun-01, Volume: 49, Issue:11

    Topics: Animals; Calcium Channel Blockers; Cisplatin; Diltiazem; Drug Evaluation, Preclinical; Drug Resistan

1989